GILEAD SCIENCES ($GILD) posted quarterly earnings results on Thursday, October 30th. The company reported earnings of $2.47 per share, beating estimates of $2.17 by $0.30. The company also reported revenue of $7,769,000,000, beating estimates of $7,595,011,738 by $173,988,262.
You can see Quiver Quantitative's $GILD stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
GILEAD SCIENCES Insider Trading Activity
GILEAD SCIENCES insiders have traded $GILD stock on the open market 31 times in the past 6 months. Of those trades, 0 have been purchases and 31 have been sales.
Here’s a breakdown of recent trading of $GILD stock by insiders over the last 6 months:
- JOHANNA MERCIER (Chief Commercial Officer) has made 0 purchases and 13 sales selling 68,000 shares for an estimated $7,688,040.
- DANIEL PATRICK O'DAY (Chairman & CEO) has made 0 purchases and 11 sales selling 60,000 shares for an estimated $6,794,835.
- ANDREW D DICKINSON (Chief Financial Officer) has made 0 purchases and 6 sales selling 15,000 shares for an estimated $1,678,000.
- JEFFREY BLUESTONE sold 5,000 shares for an estimated $548,700
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
GILEAD SCIENCES Hedge Fund Activity
We have seen 986 institutional investors add shares of GILEAD SCIENCES stock to their portfolio, and 907 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL RESEARCH GLOBAL INVESTORS removed 23,512,691 shares (-43.1%) from their portfolio in Q2 2025, for an estimated $2,606,852,051
- WELLINGTON MANAGEMENT GROUP LLP added 10,171,543 shares (+37.2%) to their portfolio in Q2 2025, for an estimated $1,127,718,972
- PRICE T ROWE ASSOCIATES INC /MD/ added 8,883,589 shares (+60.4%) to their portfolio in Q2 2025, for an estimated $984,923,512
- JPMORGAN CHASE & CO added 7,999,385 shares (+72.2%) to their portfolio in Q2 2025, for an estimated $886,891,814
- CAPITAL WORLD INVESTORS removed 7,244,602 shares (-13.5%) from their portfolio in Q2 2025, for an estimated $803,209,023
- AMERIPRISE FINANCIAL INC added 5,392,191 shares (+397.6%) to their portfolio in Q2 2025, for an estimated $597,832,216
- INVESCO LTD. added 3,394,330 shares (+33.5%) to their portfolio in Q2 2025, for an estimated $376,329,367
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
GILEAD SCIENCES Government Contracts
We have seen $21,882 of award payments to $GILD over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- LENACAPAVIR (SUNLENCA): $14,894
- SUNLENCA 300MG TAB,PKT,5: $3,882
- SUNLENCA 300MG TAB,PKT,4: $3,105
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
GILEAD SCIENCES Congressional Stock Trading
Members of Congress have traded $GILD stock 6 times in the past 6 months. Of those trades, 3 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $GILD stock by members of Congress over the last 6 months:
- REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.
- REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 3 times. They made 3 purchases worth up to $45,000 on 06/06, 05/05 and 0 sales.
- REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 05/14.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 05/12.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
GILEAD SCIENCES Analyst Ratings
Wall Street analysts have issued reports on $GILD in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 10/23/2025
- Citigroup issued a "Buy" rating on 10/08/2025
- Needham issued a "Buy" rating on 07/25/2025
- Mizuho issued a "Outperform" rating on 05/05/2025
To track analyst ratings and price targets for GILEAD SCIENCES, check out Quiver Quantitative's $GILD forecast page.
GILEAD SCIENCES Price Targets
Multiple analysts have issued price targets for $GILD recently. We have seen 8 analysts offer price targets for $GILD in the last 6 months, with a median target of $126.0.
Here are some recent targets:
- Tyler Van Buren from TD Cowen set a target price of $125.0 on 10/23/2025
- Geoff Meacham from Citigroup set a target price of $135.0 on 10/08/2025
- Chris Schott from JP Morgan set a target price of $145.0 on 09/16/2025
- Brian Abrahams from RBC Capital set a target price of $98.0 on 08/08/2025
- Asthika Goonewardene from Truist Securities set a target price of $127.0 on 08/08/2025
- Colin Bristow from UBS set a target price of $112.0 on 08/08/2025
- Joseph Stringer from Needham set a target price of $133.0 on 07/25/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
